|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Purdue_Frederick_Company
various smaller firms
Acquired by Purdue Pharma Inc. in 2007
|
|
gptkbp:advertising
|
promoted Oxy Contin
|
|
gptkbp:ceo
|
gptkb:Craig_Landau
|
|
gptkbp:clinical_trial
|
conducted for Oxy Contin
|
|
gptkbp:community_engagement
|
local health programs
|
|
gptkbp:competitors
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:conflict
|
due to lawsuits
|
|
gptkbp:controversy
|
opioid crisis
aggressive marketing tactics
aggressive marketing of opioids
|
|
gptkbp:dissolved
|
gptkb:2021
|
|
gptkbp:distribution
|
nationwide
|
|
gptkbp:employees
|
approximately 1,000
|
|
gptkbp:financial_performance
|
varied over years
|
|
gptkbp:financial_products
|
gptkb:U._S._Bankruptcy_Court_for_the_Southern_District_of_New_York
gptkb:2019
|
|
gptkbp:founded
|
gptkb:1996
|
|
gptkbp:founder
|
gptkb:John_Purdue_Gray
|
|
gptkbp:future_plans
|
restructuring plan
focus on addiction treatment
|
|
gptkbp:global_presence
|
limited to North America
|
|
gptkbp:grants
|
awarded to universities
|
|
gptkbp:headquarters
|
gptkb:Connecticut
gptkb:Stamford,_Connecticut
Stamford
|
|
gptkbp:healthcare
|
controlled substances
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Purdue Pharma L. P.
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:innovation
|
new formulations of medications
|
|
gptkbp:investment
|
in research and development
|
|
gptkbp:key_people
|
gptkb:David_Sackler
gptkb:Kathe_Sackler
gptkb:Michael_Swango
gptkb:David_A._Sackler
gptkb:J._David_Haddox
gptkb:Beverly_Sackler
gptkb:Mortimer_D._Sackler
gptkb:Richard_A._Sackler
gptkb:Robert_J._Coughlin
gptkb:John_Purdue_Gray
gptkb:Craig_Landau
gptkb:Mark_Timney
|
|
gptkbp:legal_issue
|
lawsuits
$8 billion (2020)
settlements related to opioid marketing
|
|
gptkbp:major_city
|
$4.5 billion (2021)
|
|
gptkbp:market
|
Oxy Contin (1996)
significant in pain management
|
|
gptkbp:marketing_strategy
|
direct-to-consumer advertising
|
|
gptkbp:notable_products
|
gptkb:Oxy_Contin
|
|
gptkbp:outcome
|
opioid crisis
settlements with states
|
|
gptkbp:parent_company
|
gptkb:Purdue_Pharma_Inc.
|
|
gptkbp:partnerships
|
various healthcare organizations
efforts to improve image
to address opioid crisis
|
|
gptkbp:philanthropy
|
gptkb:Purdue_Pharma_Foundation
various health initiatives
|
|
gptkbp:products
|
gptkb:healthcare_organization
none reported
opioid analgesics
|
|
gptkbp:public_perception
|
negative due to opioid crisis
|
|
gptkbp:regulatory_compliance
|
FDA scrutiny
|
|
gptkbp:research_focus
|
pain management
|
|
gptkbp:revenue
|
$3 billion (2018)
|
|
gptkbp:social_responsibility
|
initiatives to combat addiction
|
|
gptkbp:subsidiary
|
gptkb:Purdue_Pharma_Inc.
|
|
gptkbp:supply_chain
|
complex and regulated
|
|
gptkbp:sustainability
|
environmental considerations in operations
|
|
gptkbp:training
|
focused on compliance
|
|
gptkbp:treatment
|
contributed to opioid epidemic
|
|
gptkbp:type
|
private company
|
|
gptkbp:website
|
www.purduepharma.com
|
|
gptkbp:bfsParent
|
gptkb:Purdue_Pharma
|
|
gptkbp:bfsLayer
|
5
|